Quell Therapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell therapies for severe immune-mediated and inflammatory diseases. Its work focuses on restoring immune balance by harnessing Tregs to suppress harmful immune responses, with applications in autoimmune disease, chronic inflammation and organ transplant rejection. The company’s platform combines technologies for stable Treg function, targeted engineered receptors, advanced manufacturing processes and disease-specific enhancements. Quell is also progressing CAR-Treg product candidates, including autologous therapies, while exploring off-the-shelf approaches intended to make treatment faster, simpler and lower cost.
